Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

BACKGROUND: Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC). METHODS: We examined the activity of sunitinib on a continuous daily dosing (CDD) schedule in an op...

Descripción completa

Detalles Bibliográficos
Autores principales: Novello, S, Scagliotti, G V, Rosell, R, Socinski, M A, Brahmer, J, Atkins, J, Pallares, C, Burgess, R, Tye, L, Selaru, P, Wang, E, Chao, R, Govindan, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778527/
https://www.ncbi.nlm.nih.gov/pubmed/19826424
http://dx.doi.org/10.1038/sj.bjc.6605346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778527/
https://www.ncbi.nlm.nih.gov/pubmed/19826424
http://dx.doi.org/10.1038/sj.bjc.6605346

Ejemplares similares